{
    "medicine_id": "a6c70ac89dfbe242d5c9c9b922bddfbf5e9cfe30",
    "platform_id": "DB13146",
    "metadata": {
        "name": "Axumin 221 mCi 1mL Injection solution",
        "composition": "221 mCi 1mL Fluciclovine 18F",
        "clinical_particulars": {
            "therapeutic_indications": "Fluciclovine is indicated as a detection agent for positron emission tomography PET in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen PSA levels following prior treatment A31388 The overexpression of L type amino acid transporters such as LAT1 and LAT3 that mediate the uptake of essential amino acids has been extensively reported as a tumoral mechanism of cell growth A31389",
            "contraindications": {
                "disease": "The hasn t been long term carcinogenity or fertility studies in animals Even though all reports have shown no mutagenicity fluciclovine has the potential to be mutagenic L1052",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Following intravenous administration the tumor to normal tissue contrast is highest between 2 and 10 minutes after injection with a 63 reduction in mean tumor uptake at 90 minutes after injection A31390 The scanning time point should be evaluated carefully as an early scanning can present an increased blood pool and a late scanning will translate into an increased muscle uptake These variations should always be considered in the image interpretation L1050",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}